Frontier Portfolio Company Exscientia In Glaxo Collaboration

Features Dow Jones Newswires

Intellectual property commercialization specialist Frontier IP Group PLC (FIPP.LN) Monday said its portfolio company Exscientia Ltd yesterday announced that it has entered into a strategic drug discovery collaboration with GlaxoSmithKline PLC (GSK.LN).

Continue Reading Below

Shares at 0801 GMT, up 4 pence, or 11.8%, at 43 pence valuing the company at GBP16.3 million

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

July 03, 2017 04:17 ET (08:17 GMT)